MBX Biosciences Inc
Research MBX Biosciences Inc (MBX) on Bullrun: market cap USD 3.29B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMBX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.29B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 37.10M
- Free cash flow-USD 23.52M
Valuation Snapshot
latest market cap is USD 3.29B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 87.00M | -USD 81.88M | n/a | -2.38 | USD 75.29M | USD 596.00K | USD 369.22M |
| FY2024 | USD 0 | -USD 61.92M | -USD 55.56M | n/a | -5.82 | USD 49.35M | USD 171.00K | USD 257.44M |
| FY2023 | n/a | -USD 32.56M | -USD 32.11M | n/a | -31.96 | USD 30.52M | USD 324.00K | -USD 72.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.29B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.42B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 615.96M | n/a | n/a | n/a |
About MBX Biosciences Inc
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MBX Biosciences Inc's market cap?
MBX Biosciences Inc's market capitalization is USD 3.29B.
What does MBX Biosciences Inc do?
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.